Insilico Medicine (“Indelico”), a general artificial intelligence (AI) (AI), Rentosertib (formerly known as ISM001-055), has recently been awarded an official generation with the names adopted by ISM001-055. Rentosertib is the first research drug to discover both the biological goal and the therapeutic union using a genetic AI.
Idiopathic pulmonary fibrosis (IPF) is a chronic, scary pulmonary disease characterized by progressive and irreversible decrease in lung function. Affecting about 5 million people worldwide, the IPF has a poor prognosis, with an average survival of 3 to 4 years. Current treatments, including anti -corruption drugs, can slow down the disease, but not stop or reverse, leaving a significant need for more efficient treatments for modification of the disease.
Insilico has adopted an innovative approach to IPF investigation, utilizing the pharm.ai platform to discover innovative therapeutic with the ability to stop or even reverses the progression of the disease. The process started with Pandaomics, the platform’s biology engine, which analyzed huge omics and clinical sets of data to determine TNIK (Traf2 and NCK-Allege) as a promising new target for IPF. Based on this discovery, the researchers used chemistry42, the platform’s genetic chemistry mechanism, to quickly design and optimize the new small molecule compounds targeted by TNIK, leading to the appointment of Rentosertib as a preclinical candidate.
This integrated flow of work driven by AI drastically accelerated the development schedule, proceeds from the original target recognition to a preclinical candidate in just 18 months, as described in detail in Insilico’s Nature biotechnology The document published in March 2024. Specifically, the name Rentosertib is partially derived from Feng Ren, PhD, co-CCOs of Insilico and chief scientific employee who was also the first author of the Publication of Landscapes.
This is an important time for the pharmaceutical industry and the AI ​​- Rentosertib is the first medicine whose goal and design have been discovered by the modern genetic AI and has now achieved a formal name on the road to patients. The name Rentosertib is of particular importance to us, as it not only honors the contributions of Dr. Ren, but also emphasizes the essential interaction between human scientific expertise and artificial intelligence in promoting this innovative program. We hope that Rentosertib’s success in the IPF will pave the way for faster and more cost -effective discoveries of rescue treatments for many other diseases that use AI. ”
Alex Zhavoronkov, founder and CEO of Insilico Medicine
“I have the honor of seeing and driving Rentosertib from Discovery Target in the development of clinics,” said Feng Ren, PhD, co-director and chief scientific employee of Insilico Medicine, “a formal general name is usually referred to as a scientific list and the future of the list.
Currently, Rentosertib has successfully proceeded through multiple clinical trials with encouraging results. In two Phase I tests conducted in New Zealand and China, Rentosertib was orally administered to healthy people in phase I tests, delivering consistent results. Studies have shown a favorable profile of safety, tolerance and pharmacokinetics (PK) of Rentosertib, providing strong evidence to support its development in Phase II clinical trials.
Based on this institution, Indico conducted Phase IIA clinical trial in IPF patients to evaluate the effectiveness of Rentosertib. In this 12 -week Phase IIA study, Rentosertib met with the main final point of security and tolerance at all dose levels. The positive results were also mentioned for the final point of secondary efficiency, where the dose -dependent (FVC) dose. The basic findings from Phase IIA include:
-
Improvements dependent on dose in lung function: Patients receiving rentosertib showed greater improvements in the capacity of the lungs as measured by FVC. In the highest doses of 60mg QD, patients showed a medium improvement of FVC 98.4 ml from the initial value, compared to the average decrease in FVC change from the initial value of -62.3 ml for patients in the placebo group.
-
Additional improved clinical results: A similar trend-related trend was observed in other measures-for example, high-dose patients showed a slight improvement in the percentage of FVC (normalization of the pulmonary capacity for age and size), while the placebo group decreased. Patients receiving rentosertib also reported improvements in quality of life, such as coughing and overall respiratory symptoms in the highest dose.
-
Strong security and tolerance: Rentosertib continued to display a favorable safety profile in patients and the drug was well tolerated by all dosage groups. Most drug -related side effects were mild to moderate. No serious side effects associated with rentosertib were reported and security findings were consistent with those observed in previous Phase I tests.
With the positive results of Phase IIA and a formal USAN name, Indelico plans to deal with global regulators and launch larger basic tests to further evaluate the effectiveness of the Rentosertib in the IPF. Intilico is dedicated to promoting Rentosertib, with the aim of becoming the first treatment discovered by AI to approach patients, providing a critical new choice for those affected by the IPF and projecting the transformation potential of genetics in acceleration of medical discoveries.
